LRRK2 and Parkinson disease: In addition, in August 2020, a San Francisco-based biotech company announced a $1-billion deal to develop therapies targeting the LRRK2 protein, an overactive gene in PD, which clearly underscores that the PD field is pursuing the oncology approach, adding another genetic target to the growing list, increasing the hopes for patients with PD that there may be disease modifying remedies in the next decades to come, at least for subsets of patients with PD.